Improved Oncolytic Reovirus
OwnerMaya Shmulevitz, Adil Mohamed +2inventors
InventorsMaya Shmulevitz, Adil Mohamed, Mary Hitt, Wan Kong Yip
Life of this patent
Estimating the term…
Abstract
The present disclosure provides modified reovirus with improved characteristics, including improved oncolytic activity. Reoviruses provided herein include resortant viruses as well as viruses expressing mutated proteins. Methods of using such modified reovirus for inducing cancer cell lysis as well as treatment of cancer are disclosed. Also provided are methods tailored for induction of a desired cytokine profile in conjunction with, e.g., methods of inducing cancer cell oncolysis.
Claims104
A reovirus genetically modified to express at least one protein from the reovirus T3DPL, wherein the protein is:
- T3DPL σ3, T3DPL μ2, or T3DPL λ1.
The reovirus of any one of the preceding claims, wherein the reovirus expresses T3DPL λ1.
The reovirus of any one of the preceding claims, wherein the reovirus is a T3D strain other than T3DPL.
The reovirus of any one of the preceding claims, wherein the reovirus is T3DTD strain.
The reovirus of any one of the preceding claims, wherein the reovirus is T3DATTC strain.
A T3DPL reovirus genetically modified to express a T3DPL reovirus σ3 protein comprising a substitution of lysine at position 198, wherein the numbering of the amino acid position is with reference to the amino acid sequence of T3DPL reovirus σ3 protein set forth in SEQ ID NO:4.
A T3DPL reovirus genetically modified to express a T3DPL reovirus σ1 protein comprising a mutation in the tail domain of the σ1 protein, wherein the mutation comprises a substitution of Leucine at position 28 or a substitution of serine at position 66 with reference to the amino acid sequence of wild type T3DPL reovirus σ1 protein set forth in SEQ ID NO:1.
A T3DPL reovirus genetically modified to express a T3DPL reovirus λ2 protein comprising a mutation in a FLAP domain, wherein the FLAP domain comprises amino acids 1023-1274, wherein the numbering of the amino acids is with reference to the amino acid sequence of T3DPL reovirus λ2 protein as set forth in SEQ ID NO:9, wherein the reovirus expresses wild type T3DPL reovirus λ1 and λ3 proteins.
A T3DPL reovirus genetically modified to express a T3DPL reovirus λ2 protein comprising a substitution of isoleucine at position 1274 or aparagine at position 1148 with reference to the amino acid sequence of wild type T3DPL reovirus λ2 protein set forth in SEQ ID NO:9.
A T3DPL reovirus genetically modified to express:
- a T3DPL reovirus λ2 protein comprising a substitution of methionine at position 1101 with reference to the amino acid sequence of wild type T3DPL reovirus λ2 protein set forth in SEQ ID NO:9;
- a T3DPL reovirus λ3 protein comprising a substitution at position 892, wherein the numbering of the amino acid position is with reference to the amino acid sequence of wild type T3DPL reovirus λ3 protein set forth in SEQ ID NO:8;
- and
- a T3DPL reovirus σ3 protein comprising a substitution at position 230, wherein the numbering of the amino acid position is with reference to the amino acid sequence of wild type T3DPL reovirus σ3 protein set forth in SEQ ID NO:4.
A T3DPL reovirus genetically modified to express a T3DPL reovirus σ1 protein comprising a mutation in the head domain, body domain, and/or tail domain, wherein:
- the head domain extends from amino acid 296-455,
- the body domain extends from amino acid 155-289,
- the tail domain extends from amino acid 28-154, and
- the numbering of the amino acid positions is with reference to the amino acid sequence of T3DPL reovirus σ1 protein set forth in SEQ ID NO:1.
A T3DPL reovirus genetically modified to express a T3DPL reovirus λ1 protein comprising a mutation at or adjacent the amino acid position 962 and/or 122 of the λ1 protein, wherein the numbering of the amino acid positions is with reference to the amino acid sequence of T3DPL reovirus λ1 protein set forth in SEQ ID NO:10.
A T3DPL reovirus genetically modified to express:
- a T3DPL reovirus λ1 protein comprising a mutation at or adjacent amino acid position 122 of the λ1 protein, wherein the numbering of the amino acid positions is with reference to the amino acid sequence of T3DPL reovirus λ1 protein set forth in SEQ ID NO:10;
- T3DPL reovirus λ3 protein comprising a mutation at or adjacent amino acid position 972 of the λ3 protein, wherein the numbering of the amino acid position is with reference to the amino acid sequence of T3DPL reovirus λ3 protein set forth in SEQ ID NO:8;
- and
- T3DPL reovirus σ3 protein comprising a mutation at or adjacent amino acid position 64 of the σ3 protein, wherein the numbering of the amino acid position is with reference to the amino acid sequence of T3DPL reovirus σ3 protein set forth in SEQ ID NO:4.
A T3D reovirus genetically modified to express a mutant σ1 protein comprising a mutation in the body domain relative to a wild type σ1 protein, wherein the mutation in the body domain renders the mutant σ1 protein resistant to cleavage by the metalloprotease as compared to the wild type σ1 protein.
A T3DPL reovirus genetically modified to express T3DTD σ3 protein instead of the endogenous T3DPL σ3 protein.
A T3DTD reovirus genetically modified to express T3DPL σ3 protein instead of the endogenous T3DTD σ3 protein.
A method for inducing a high interferon (IFN)-dependent cytokines response in a subject, the method comprising administering a therapeutically effective amount of a T3DTD to the subject, wherein high IFN cytokines response comprises an IFN cytokines response that is higher than that induced by T3DPL.
A method for inducing a low interferon (IFN)-dependent cytokines response in a subject, the method comprising administering a therapeutically effective amount of a T3DPL to the subject, wherein the low IFN cytokines response comprises an IFN cytokines response that is lower than that induced by T3DTD.
A method for inducing a high interferon (IFN)-independent, NF-κB-dependent cytokines response in a subject, the method comprising administering a therapeutically effective amount of a T3DPL to the subject, wherein the high IFN-independent, NF-κB-dependent cytokines response comprises a response that is higher than an IFN-independent, NF-κB-dependent cytokines response induced by T3DTD.
A method for inducing a high interferon (IFN)-independent, NF-κB-dependent cytokines response in a subject, the method comprising administering a therapeutically effective amount of a T3DTD genetically modified to express a σ3 protein of T3DPL to the subject, wherein the high IFN-independent, NF-κB-dependent cytokines response comprises a response higher than an IFN-independent, NF-κB-dependent cytokines response induced by T3DTD expressing a T3DTD σ3 protein.
A method for inducing a low IFN-independent, NF-κB-dependent cytokines response in a subject, the method comprising administering a therapeutically effective amount of a T3DTD to the subject, wherein the low IFN-independent, NF-κB-dependent cytokines response comprises a IFN-independent, NF-κB-dependent cytokines response that is lower than that induced by T3DPL.
A method for inducing low IFN-independent, NF-κB-dependent cytokines response in a subject, the method comprising administering a therapeutically effective amount of a T3DPL genetically modified to express a σ3 protein of T3DTD to the subject, wherein the low IFN-independent, NF-κB-dependent cytokines response comprises a IFN-independent, NF-κB-dependent cytokines response that is lower than that induced by T3DPL expressing a T3DPL σ3 protein.
The method of claim IFN-independent, NF-κB-dependent cytokines response comprises expression of one or more of Cxcl1, Csf2, Cxcl2, and Fas.
A T3DPL reovirus genetically modified to express a T3DPL reovirus σ1 protein comprising a substitution of serine at position 66 in the σ1 protein with reference to the amino acid sequence of wild type T3DPL reovirus σ1 protein set forth in SEQ ID NO:1 and to express a T3DPL reovirus λ2 protein comprising a substitution of isoleucine at position 1274, wherein the numbering of the amino acids is with reference to the amino acid sequence of T3DPL reovirus λ2 protein as set forth in SEQ ID NO:9.
A T3DPL reovirus genetically modified to express a T3DPL reovirus λ2 protein comprising a substitution of isoleucine at position 1274, wherein the numbering of the amino acids is with reference to the amino acid sequence of T3DPL reovirus λ2 protein as set forth in SEQ ID NO:9 and to express a T3DPL reovirus σ1 protein comprising a substitution at amino acid position 312, wherein the numbering of the amino acid position is with reference to the amino acid sequence of T3DPL reovirus σ1 protein set forth in SEQ ID NO:1.
A T3DPL reovirus genetically modified to express a T3DPL reovirus σ1 protein comprising the substitution S18I, a T3DPL reovirus σ3 protein comprising the substitution K64E, T3DPL reovirus μ2 protein comprising the substitution A612V, λ2 protein comprising the substitution I1274T, and λ1 protein comprising the substitution A962S.
A T3DPL reovirus genetically modified to express a T3DPL reovirus σ1 protein comprising the substitution R219Q, a T3DPL reovirus σ3 protein comprising the substitution K64E, T3DPL reovirus μ2 protein comprising the substitution A612V, λ2 protein comprising the substitution I1274T, and λ1 protein comprising the substitution A962S.
Dependencies are inferred from the claim text.